{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T15:59:19Z","timestamp":1768319959965,"version":"3.49.0"},"reference-count":59,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T00:00:00Z","timestamp":1553040000000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7,1]]},"DOI":"10.1093\/jac\/dkz099","type":"journal-article","created":{"date-parts":[[2019,3,15]],"date-time":"2019-03-15T12:12:24Z","timestamp":1552651944000},"page":"2030-2038","source":"Crossref","is-referenced-by-count":8,"title":["High predictive efficacy of integrase strand transfer inhibitors in perinatally HIV-1-infected African children in therapeutic failure of first- and second-line antiretroviral drug regimens recommended by the WHO"],"prefix":"10.1093","volume":"74","author":[{"given":"Ralph-Sydney","family":"Mboumba Bouassa","sequence":"first","affiliation":[{"name":"Laboratoire de Virologie, H\u00f4pital Europ\u00e9en Georges Pompidou, Paris, France"},{"name":"Ecole Doctorale (ED562) Bio Sorbonne Paris Cit\u00e9 (BioSPC), Universit\u00e9 Paris Descartes, Paris, France"},{"name":"Ecole Doctorale R\u00e9gionale en Infectiologie Tropicale, Franceville, Gabon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian Diamant","family":"Mossoro-Kpinde","sequence":"additional","affiliation":[{"name":"Laboratoire National de Biologie Clinique et de Sant\u00e9 Publique, Bangui, R\u00e9publique Centrafricaine"},{"name":"Facult\u00e9 des Sciences de la Sant\u00e9, Universit\u00e9 de Bangui, Bangui, R\u00e9publique Centrafricaine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Chrysostome","family":"Gody","sequence":"additional","affiliation":[{"name":"Facult\u00e9 des Sciences de la Sant\u00e9, Universit\u00e9 de Bangui, Bangui, R\u00e9publique Centrafricaine"},{"name":"Complexe P\u00e9diatrique de Bangui, Bangui, R\u00e9publique Centrafricaine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Veyer","sequence":"additional","affiliation":[{"name":"Laboratoire de Virologie, H\u00f4pital Europ\u00e9en Georges Pompidou, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"P\u00e9r\u00e9","sequence":"additional","affiliation":[{"name":"Laboratoire de Virologie, H\u00f4pital Europ\u00e9en Georges Pompidou, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathieu","family":"Matta","sequence":"additional","affiliation":[{"name":"Laboratoire de Virologie, H\u00f4pital Europ\u00e9en Georges Pompidou, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leman","family":"Robin","sequence":"additional","affiliation":[{"name":"Laboratoire de Virologie, H\u00f4pital Europ\u00e9en Georges Pompidou, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e9rard","family":"Gr\u00e9senguet","sequence":"additional","affiliation":[{"name":"Facult\u00e9 des Sciences de la Sant\u00e9, Universit\u00e9 de Bangui, Bangui, R\u00e9publique Centrafricaine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Charpentier","sequence":"additional","affiliation":[{"name":"INSERM, IAME, UMR 1137, Paris, France"},{"name":"Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, Paris, France"},{"name":"AP-HP, H\u00f4pital Bichat-Claude Bernard, Laboratoire de Virologie, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"B\u00e9lec","sequence":"additional","affiliation":[{"name":"Laboratoire de Virologie, H\u00f4pital Europ\u00e9en Georges Pompidou, Paris, France"},{"name":"Universit\u00e9 Paris Descartes, Sorbonne Paris Cit\u00e9, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,3,19]]},"reference":[{"key":"2019062107401084300_dkz099-B1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1086\/430741","article-title":"Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated","volume":"192","author":"Johnson","year":"2005","journal-title":"J Infect Dis"},{"key":"2019062107401084300_dkz099-B2","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S1473-3099(08)70180-4","article-title":"Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa","volume":"8","author":"Sutcliffe","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"2019062107401084300_dkz099-B3","doi-asserted-by":"crossref","first-page":"e1000430","DOI":"10.1371\/journal.pmed.1000430","article-title":"HIV-1 drug resistance emergence among breastfeeding infants born to HIV-infected mothers during a single-arm trial of triple-antiretroviral prophylaxis for prevention of mother-to-child transmission: a secondary analysis","volume":"8","author":"Zeh","year":"2011","journal-title":"PLoS Med"},{"key":"2019062107401084300_dkz099-B4","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1093\/infdis\/jit110","article-title":"Impact of antiretroviral drugs in pregnant women and their children in Africa: HIV resistance and treatment outcomes","volume":"207","author":"Paredes","year":"2013","journal-title":"J Infect Dis"},{"key":"2019062107401084300_dkz099-B5","doi-asserted-by":"crossref","first-page":"21140","DOI":"10.7448\/IAS.19.1.21140","article-title":"High levels of pre-treatment HIV drug resistance and treatment failure in Nigerian children","volume":"19","author":"Boerma","year":"2016","journal-title":"J Int AIDS Soc"},{"key":"2019062107401084300_dkz099-B6","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1089\/aid.2015.0215","article-title":"HIV drug resistance among children initiating first-line antiretroviral treatment in Uganda","volume":"3","author":"Kityo","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2019062107401084300_dkz099-B7","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jac\/dkw463","article-title":"Alarming increase in pretreatment HIV drug resistance in children living in sub-Saharan Africa: a systematic review and meta-analysis","volume":"72","author":"Boerma","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2019062107401084300_dkz099-B8","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/QAI.0000000000001553","article-title":"High prevalence of HIV drug resistance among newly diagnosed infants aged <18 months: results from a nationwide surveillance in Nigeria","volume":"77","author":"Inzaule","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2019062107401084300_dkz099-B9","doi-asserted-by":"crossref","first-page":"e283","DOI":"10.1097\/INF.0b013e3181ba6c92","article-title":"Risk of extended viral resistance in human immunodeficiency virus-1-infected Mozambican children after first-line treatment failure","volume":"28","author":"Vaz","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"2019062107401084300_dkz099-B10","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S1473-3099(11)70141-4","article-title":"HIV-1-resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: a systematic review","volume":"11","author":"Sigaloff","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"2019062107401084300_dkz099-B11","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1089\/aid.2011.0035","article-title":"Virological response and resistance profiles after 18 to 30 months of first- or second-\/third-line antiretroviral treatment: a cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic","volume":"28","author":"Charpentier","year":"2012","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2019062107401084300_dkz099-B12","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1089\/aid.2011.0300","article-title":"High rate of antiretroviral drug resistance mutations in HIV type 1-infected Senegalese children in virological failure on first-line treatment according to the World Health Organization guidelines","volume":"29","author":"Kebe","year":"2013","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2019062107401084300_dkz099-B13","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1089\/aid.2012.0218","article-title":"Short communication: high rates of thymidine analogue mutations and dual-class resistance among HIV-infected Ugandan children failing first-line antiretroviral therapy","volume":"29","author":"Sigaloff","year":"2013","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2019062107401084300_dkz099-B14","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1093\/jac\/dkw218","article-title":"Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa","volume":"71","author":"Boender","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2019062107401084300_dkz099-B15","doi-asserted-by":"crossref","first-page":"20683.","DOI":"10.7448\/IAS.19.1.20683","article-title":"High rates of virological failure and drug resistance in perinatally HIV-1-infected children and adolescents receiving lifelong antiretroviral therapy in routine clinics in Togo","volume":"19","author":"Salou","year":"2016","journal-title":"J Int AIDS Soc"},{"key":"2019062107401084300_dkz099-B16","doi-asserted-by":"crossref","first-page":"e6282.","DOI":"10.1097\/MD.0000000000006282","article-title":"High levels of virological failure with major genotypic resistance mutations in HIV-1-infected children after 5 years of care according to WHO-recommended 1st-line and 2nd-line antiretroviral regimens in the Central African Republic: a cross-sectional study","volume":"96","author":"Mossoro-Kpinde","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"2019062107401084300_dkz099-B17","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S1473-3099(17)30702-8","article-title":"HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis","volume":"18","author":"Gupta","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2019062107401084300_dkz099-B18","doi-asserted-by":"crossref","first-page":"E60.","DOI":"10.3390\/v10020060","article-title":"High levels of dual-class drug resistance in HIV-infected children failing first-line antiretroviral therapy in Southern Ethiopia","volume":"10","author":"Tadesse","year":"2018","journal-title":"Viruses"},{"key":"2019062107401084300_dkz099-B19","year":"2016"},{"key":"2019062107401084300_dkz099-B20","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1038\/s41598-018-22914-5","article-title":"Analyses of HIV-1 integrase sequences prior to South African national HIV-treatment program and available of integrase inhibitors in Cape Town, South Africa","volume":"8","author":"Brado","year":"2018","journal-title":"Sci Rep"},{"key":"2019062107401084300_dkz099-B21","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/cid\/cit696","article-title":"Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years","volume":"58","author":"Nachman","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2019062107401084300_dkz099-B22","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s40265-015-0446-2","article-title":"Use of integrase inhibitors in HIV-infected children and adolescents","volume":"75","author":"Dehority","year":"2015","journal-title":"Drugs"},{"key":"2019062107401084300_dkz099-B23","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1093\/jpids\/piu146","article-title":"Pharmacokinetics and 48-week safety and efficacy of raltegravir for oral suspension in human immunodeficiency virus type-1-infected children 4 weeks to 2 years of age","volume":"4","author":"Nachman","year":"2015","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2019062107401084300_dkz099-B24","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1097\/INF.0000000000000848","article-title":"Safety, pharmacokinetics and efficacy of dolutegravir in treatment-experienced HIV-1 infected adolescents: forty-eight-week results from IMPAACT P1093","volume":"34","author":"Viani","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"2019062107401084300_dkz099-B25","doi-asserted-by":"crossref","first-page":"37.","DOI":"10.1186\/s13052-018-0469-x","article-title":"Dolutegravir-based anti-retroviral therapy is effective and safe in HIV-infected paediatric patients","volume":"44","author":"Bruzzese","year":"2018","journal-title":"Ital J Pediatr"},{"key":"2019062107401084300_dkz099-B26","year":"2018"},{"key":"2019062107401084300_dkz099-B27","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1056\/NEJMc1807653","article-title":"Neural-tube defects with dolutegravir treatment from the time of conception","volume":"379","author":"Zash","year":"2018","journal-title":"N Engl J Med"},{"key":"2019062107401084300_dkz099-B28","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/QAI.0b013e318183acae","article-title":"High prevalence of antiretroviral drug resistance mutations in HIV-1 non-B subtype strains from African children receiving antiretroviral therapy regimen according to the 2006 revised WHO recommendations","volume":"49","author":"Gody","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2019062107401084300_dkz099-B29","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1089\/aid.2010.0091","article-title":"First data on HIV-1 resistance mutations to antiretroviral drugs in Central African Republic","volume":"26","author":"Moussa","year":"2010","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2019062107401084300_dkz099-B30","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.3851\/IMP1896","article-title":"Surveillance of antiretroviral drug resistance mutations in untreated young children living in the Central African Republic","volume":"16","author":"Charpentier","year":"2011","journal-title":"Antivir Ther"},{"key":"2019062107401084300_dkz099-B31","year":"2017"},{"key":"2019062107401084300_dkz099-B32","year":"2018"},{"key":"2019062107401084300_dkz099-B33","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/jac\/dkq099","article-title":"HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens","volume":"65","author":"da Silva","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2019062107401084300_dkz099-B34","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1089\/aid.2012.0058","article-title":"Genetic diversity and naturally polymorphisms in HIV type 1 integrase isolates from Maputo, Mozambique: implications for integrase inhibitors","volume":"28","author":"Oliveira","year":"2012","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2019062107401084300_dkz099-B35","doi-asserted-by":"crossref","first-page":"5013","DOI":"10.3390\/ijms14035013","article-title":"Genetic analysis of HIV-1 integrase sequences from treatment naive individuals in northeastern South Africa","volume":"14","author":"Bessong","year":"2013","journal-title":"Int J Mol Sci"},{"key":"2019062107401084300_dkz099-B36","first-page":"127","article-title":"The prediction of integrase inhibitors efficacy in third line regimen after first and second line antiretroviral therapy failure in Senegal","volume":"6","author":"Tchiakpe","year":"2014","journal-title":"J Antivir Antiretrovir"},{"key":"2019062107401084300_dkz099-B37","doi-asserted-by":"crossref","first-page":"369.","DOI":"10.1186\/s13104-018-3492-5","article-title":"Prevalence of resistance to integrase strand-transfer inhibitors (INSTIs) among untreated HIV-1 infected patients in Morocco","volume":"11","author":"Alaoui","year":"2018","journal-title":"BMC Res Notes"},{"key":"2019062107401084300_dkz099-B38","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1089\/aid.2011.0326","article-title":"Drug resistance mutations of HIV type 1 non-B viruses to integrase inhibitors in treatment-naive patients from sub-Saharan countries and discordant interpretations","volume":"28","author":"Monleau","year":"2012","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2019062107401084300_dkz099-B39","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1089\/aid.2011.0266","article-title":"Short communication: analysis of the integrase gene from HIV type 1-positive patients living in a rural area of West Cameroon","volume":"28","author":"Turriziani","year":"2012","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2019062107401084300_dkz099-B40","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1089\/aid.2018.0006","article-title":"Prevalence of integrase strand transfer inhibitors resistance mutations in integrase strand transfer inhibitors-naive and -experienced HIV-1 infected patients: a single center experience","volume":"34","author":"De Francesco","year":"2018","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2019062107401084300_dkz099-B41","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1177\/135965350701200411","article-title":"Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance","volume":"12","author":"Lataillade","year":"2007","journal-title":"Antivir Ther"},{"key":"2019062107401084300_dkz099-B42","doi-asserted-by":"crossref","first-page":"6058","DOI":"10.1128\/JVI.00495-16","article-title":"HIV-1 protease, reverse transcriptase, and integrase variation","volume":"90","author":"Rhee","year":"2016","journal-title":"J Virol"},{"key":"2019062107401084300_dkz099-B43","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000484692","article-title":"Resistance-associated mutations and polymorphisms among integrase inhibitor-na\u00efve HIV-1 patients in Kuwait","volume":"60","author":"Chehadeh","year":"2017","journal-title":"Intervirology"},{"key":"2019062107401084300_dkz099-B44","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/nar\/gkg100","article-title":"Human immunodeficiency virus reverse transcriptase and protease sequence database","volume":"31","author":"Rhee","year":"2003","journal-title":"Nucleic Acids Res"},{"key":"2019062107401084300_dkz099-B45","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1093\/jac\/dky005","article-title":"Primary resistance to integrase strand transfer inhibitors in patients infected with diverse HIV-1 subtypes in sub-Saharan Africa","volume":"73","author":"Inzaule","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2019062107401084300_dkz099-B46","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1128\/AAC.01209-10","article-title":"In vitro antiretroviral properties of S\/GSK1349572, a next-generation HIV integrase inhibitor","volume":"55","author":"Kobayashi","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2019062107401084300_dkz099-B47","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.antiviral.2011.03.178","article-title":"Resistance associated mutations to dolutegravir (S\/GSK1349572) in HIV-infected patients\u2014impact of HIV subtypes and prior raltegravir experience","volume":"90","author":"Garrido","year":"2011","journal-title":"Antiviral Res"},{"key":"2019062107401084300_dkz099-B48","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0140-6736(13)61221-0","article-title":"Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study","volume":"382","author":"Cahn","year":"2013","journal-title":"Lancet"},{"key":"2019062107401084300_dkz099-B49","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/135965350901400108","article-title":"Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes","volume":"14","author":"Ma\u00efga","year":"2009","journal-title":"Antivir Ther"},{"key":"2019062107401084300_dkz099-B50","doi-asserted-by":"crossref","first-page":"e0164753.","DOI":"10.1371\/journal.pone.0164753","article-title":"Switch to dolutegravir plus rilpivirine dual therapy in cART-experienced subjects: an observational cohort","volume":"11","author":"Capetti","year":"2016","journal-title":"PLoS One"},{"key":"2019062107401084300_dkz099-B51","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/jac\/dkv430","article-title":"Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients","volume":"71","author":"Gubavu","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2019062107401084300_dkz099-B52","first-page":"837","article-title":"Efficacy and tolerance of dolutegravir-based combined ART in perinatally HIV-1-infected adolescents: a French multicentre retrospective study","volume":"72","author":"Briand","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2019062107401084300_dkz099-B53","first-page":"177","article-title":"Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus","volume":"73","author":"Castagna","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2019062107401084300_dkz099-B54","doi-asserted-by":"crossref","first-page":"2040206618762985.","DOI":"10.1177\/2040206618762985","article-title":"Frequent cross-resistance to rilpivirine among subtype C HIV-1 from first-line antiretroviral therapy failures in South Africa","volume":"26","author":"Penrose","year":"2018","journal-title":"Antivir Chem Chemother"},{"key":"2019062107401084300_dkz099-B55","doi-asserted-by":"crossref","first-page":"658.","DOI":"10.1186\/s12879-017-2755-4","article-title":"A dual regimen of ritonavir\/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks\u2019 observational data","volume":"17","author":"Capetti","year":"2017","journal-title":"BMC Infect Dis"},{"key":"2019062107401084300_dkz099-B56","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3947\/ic.2018.50.3.252","article-title":"Effectiveness, safety, and tolerability of a switch to dual therapy with dolutegravir plus cobicistat-boosted darunavir in treatment-experienced patients with human immunodeficiency virus","volume":"50","author":"Lee","year":"2018","journal-title":"Infect Chemother"},{"key":"2019062107401084300_dkz099-B57","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/0091270010371113","article-title":"The effect of lopinavir\/ritonavir and darunavir\/ritonavir on the HIV integrase inhibitor S\/GSK1349572 in healthy participants","volume":"51","author":"Song","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"2019062107401084300_dkz099-B58","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/jac\/dky384","article-title":"Pharmacokinetics of dolutegravir with and without darunavir\/cobicistat in healthy volunteers","volume":"74","author":"Elliot","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2019062107401084300_dkz099-B59","year":"2013"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/74\/7\/2030\/28851759\/dkz099.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T21:27:21Z","timestamp":1663104441000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/74\/7\/2030\/5396701"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,19]]},"references-count":59,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,3,19]]},"published-print":{"date-parts":[[2019,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkz099","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,7]]},"published":{"date-parts":[[2019,3,19]]}}}